Mind Medicine Inc (MNMD) concluded trading on Thursday at a closing price of $8.65, with 4.7 million shares of worth about $40.63 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 31.26% during that period and on February 13, 2025 the price saw a gain of about 1.65%. Currently the company’s common shares owned by public are about 81.59M shares, out of which, 27.23M shares are available for trading.
Stock saw a price change of -3.57% in past 5 days and over the past one month there was a price change of 35.26%. Year-to-date (YTD), MNMD shares are showing a performance of 24.28% which increased to 81.34% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.35 but also hit the highest price of $12.22 during that period. The average intraday trading volume for Mind Medicine Inc shares is 1.68 million. The stock is currently trading 12.86% above its 20-day simple moving average (SMA20), while that difference is up 16.94% for SMA50 and it goes to 18.55% higher than SMA200.
The stock has a current market capitalization of $634.32M and its 3Y-monthly beta is at 1.75. It has posted earnings per share of -$2.09 in the same period. It has Quick Ratio of 9.00 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MNMD, volatility over the week remained 9.56% while standing at 9.70% over the month.
Stock’s fiscal year EPS is expected to rise by 41.32% while it is estimated to decrease by -4.19% in next year. EPS is likely to grow at an annualized rate of 14.93% for next 5-years, compared to annual growth of 2.29% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Evercore ISI on January 28, 2025 offering an Outperform rating for the stock and assigned a target price of $23 to it. Coverage by Chardan Capital Markets stated Mind Medicine Inc (MNMD) stock as a Buy in their note to investors on December 20, 2024, suggesting a price target of $20 for the stock. On October 14, 2024, Leerink Partners Resumed their recommendations, while on July 24, 2024, ROTH MKM Initiated their ratings for the stock with a price target of $36. Stock get an Outperform rating from Robert W. Baird on May 29, 2024.
